RESUMEN
To investigate the association between physical activity (PA) domains and chronic low back pain (LBP) in older adults. A cross-sectional study where sociodemographic, behavioral, and health variables; PA; and presence of chronic LBP were collected. Higher scores of PA defined the "more active" participants. Binary logistic regression was used to test the association between PA domains and chronic LBP. A total of 516 participants were included. The mean age was 71.8 (95% confidence interval, CI, [71.1, 72.5]) years, and 29%, 27%, 25%, and 31% were identified as "more active" in the household, sports, leisure-time, and total PA domains, respectively. "More active" participants in sports (odds ratio = 0.62, 95% CI [0.40, 0.97]), leisure-time (odds ratio = 0.54, 95% CI [0.35, 0.85]) and total (odds ratio = 0.60, 95% CI [0.39, 0.92]) PA domains were less likely to report chronic LBP. High levels of sports, leisure-time, and total PA were inversely associated with chronic LBP.
Asunto(s)
Dolor de la Región Lumbar , Deportes , Humanos , Anciano , Estudios Transversales , Vida Independiente , Ejercicio FísicoRESUMEN
Sirtuins (SIRTs) are seven nicotinamide adenine dinucleotide (NAD+)-dependent protein deacetylases enzymes (SIRT1-7) that play an important role in maintaining cellular homeostasis. Among those, the most studied are SIRT1 and SIRT3, a nuclear SIRT and a mitochondrial SIRT, respectively, which significantly impact with an increase in mammals' lifespan by modulating metabolic cellular processes. Particularly, when activated, both SIRT1 and 3 enhance pancreatic ß-cells' insulin release and reduce inflammation and oxidative stress pancreatic damage, maintaining then glucose homeostasis. Therefore, SIRT1 and 3 activators have been proposed to prevent and counteract metabolic age-related diseases, such as type 2 diabetes mellitus (T2DM). Physical activity (PA) has a well-established beneficial effect on phenotypes of aging like ß-cell dysfunction and diabetes mellitus. Recent experimental and clinical evidence reports that PA increases the expression levels of both SIRT1 and 3, suggesting that PA may exert its healthy contribute even by activating SIRTs. Therefore, in the present article, we discuss the role of SIRT1, SIRT3, and PA on ß-cell function and on diabetes. We also discuss the possible interaction between PA and activation of SIRTs as a possible therapeutic strategy to maintain glucose hemostasis and to prevent T2DM and its complications, especially in the elderly population.
Asunto(s)
Glucosa/metabolismo , Homeostasis , Sirtuina 1/química , Sirtuina 3/química , Animales , Diabetes Mellitus Tipo 2/etiología , Diabetes Mellitus Tipo 2/metabolismo , Susceptibilidad a Enfermedades , Ejercicio Físico , Humanos , Células Secretoras de Insulina/metabolismo , Enfermedades Metabólicas/etiología , Enfermedades Metabólicas/metabolismo , Sirtuina 1/metabolismo , Sirtuina 3/metabolismoRESUMEN
AIMS: Almost no data are available on whether patients and doctors have similar or dissimilar opinions on the presence and level of distress due to antipsychotic adverse effects. The aim of this survey is to compare doctors' versus patients' perspective on the presence and level of distress due to antipsychotic adverse effects in a sample of patients under the care of the South-Verona mental health services. METHODS: All patients exposed to antipsychotic drugs during a census period of 6 months were identified. For each included subject, socio-demographic, clinical and treatment data were extracted. Patients' perspective on antipsychotic adverse effects was measured by means of the Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS). The LUNSERS was similarly employed to measure doctors' perspective on antipsychotic adverse effects. RESULTS: During the recruitment period, 243 patients taking antipsychotic drugs were enrolled. The correlation between the total LUNSERS score reported by patients and doctors was very low (correlation coefficient 0.22, 95% confidence interval 0.15-0.30). On average, patients perceived more adverse effects and with a significant higher distress than doctors. Multivariate analyses found no factors simultaneously associated with both patient and doctor ratings of adverse effects. CONCLUSION: Our study suggests that doctors, researchers and health care providers should increasingly consider patient and doctor perspectives as two complementary dimensions that may provide different insights in the evaluation of antipsychotic drugs. Integrating different points of view may represent a way to develop a better therapeutic alliance that might decrease the likelihood of nonadherence.
Asunto(s)
Antipsicóticos/efectos adversos , Actitud del Personal de Salud , Actitud Frente a la Salud , Médicos , Adulto , Antipsicóticos/uso terapéutico , Servicios Comunitarios de Salud Mental , Recolección de Datos , Femenino , Humanos , Italia , Masculino , Persona de Mediana Edad , Relaciones Médico-Paciente , Adulto JovenRESUMEN
This multisite study was conducted to compare the efficacy and tolerability of combination treatment with clozapine plus aripiprazole versus combination treatment with clozapine plus haloperidol in patients with schizophrenia who do not have an optimal response to clozapine. Patients continued to take clozapine and were randomly assigned to receive daily augmentation with aripiprazole or haloperidol. Physicians prescribed the allocated treatments according to usual clinical care. Withdrawal from allocated treatment within 3 months was the primary outcome. Secondary outcomes included severity of symptoms on the Brief Psychiatric Rating Scale and antipsychotic subjective tolerability on the Liverpool University Neuroleptic Side Effect Rating Scale. A total of 106 patients with schizophrenia were randomly assigned to treatment. After 3 months, we found no difference in the proportion of patients who discontinued treatment between the aripiprazole and haloperidol groups (13.2% vs 15.1%, P = 0.780). The 3-month change of the Brief Psychiatric Rating Scale total score was similar in the aripiprazole and haloperidol groups (-5.9 vs -4.4 points, P = 0.523), whereas the 3-month decrease of the Liverpool University Neuroleptic Side Effect Rating Scale total score was significantly higher in the aripiprazole group than in the haloperidol group (-7.4 vs -2.0 points, P = 0.006). These results suggest that augmentation of clozapine with aripiprazole offers no benefit with regard to treatment withdrawal and overall symptoms in schizophrenia compared with augmentation with haloperidol. However, an advantage in the perception of adverse effects with aripiprazole treatment may be meaningful for patients.
Asunto(s)
Antipsicóticos/uso terapéutico , Clozapina/uso terapéutico , Quimioterapia Combinada/métodos , Haloperidol/uso terapéutico , Piperazinas/uso terapéutico , Quinolonas/uso terapéutico , Esquizofrenia/tratamiento farmacológico , Adulto , Antipsicóticos/administración & dosificación , Antipsicóticos/efectos adversos , Aripiprazol , Escalas de Valoración Psiquiátrica Breve , Clozapina/administración & dosificación , Clozapina/efectos adversos , Resistencia a Medicamentos , Quimioterapia Combinada/efectos adversos , Femenino , Haloperidol/administración & dosificación , Haloperidol/efectos adversos , Humanos , Masculino , Piperazinas/administración & dosificación , Piperazinas/efectos adversos , Quinolonas/administración & dosificación , Quinolonas/efectos adversosRESUMEN
BACKGROUND: It is unclear whether the use of selective serotonin reuptake inhibitors (SSRIs) and other antidepressant drugs reduce the risk of suicide in people with depression. We explored the association between exposure to SSRIs and risk of suicide completion or attempt. METHODS: We conducted a systematic review of observational studies that reported completed or attempted suicide in depressed individuals who were exposed to SSRIs compared with those who were not exposed to antidepressants. We assessed the overall risk of completed or attempted suicide. RESULTS: Eight studies involving more than 200 000 patients with moderate or severe depression were included in the meta-analysis. Although exposure to SSRIs increased the risk of completed or attempted suicide among adolescents (odds ratio [OR] 1.92, 95% confidence interval [CI] 1.51-2.44), the risk was decreased among adults (OR 0.57, 95% CI 0.47-0.70). Among people aged 65 or more years, exposure to SSRIs had a protective effect (OR 0.46, 95% CI 0.27-0.79). Sensitivity analyses did not change these findings. In particular, for studies that used completed suicide as an outcome, exposure to SSRIs was associated with increased risk among adolescents (OR 5.81, 95% CI 1.57-21.51) and decreased risk among adults (OR 0.66, 95% CI 0.52-0.83) and older people (OR 0.53, 95% CI 0.26-1.06). INTERPRETATION: Based on data from observational studies, use of SSRIs may be associated with a reduced risk of suicide in adults with depression. Among adolescents, use of SSRIs may increase suicidality.
Asunto(s)
Inhibidores Selectivos de la Recaptación de Serotonina/efectos adversos , Suicidio , Adolescente , Conducta del Adolescente/psicología , Factores de Edad , Intervalos de Confianza , Depresión/tratamiento farmacológico , Humanos , Oportunidad Relativa , Medición de RiesgoRESUMEN
The persistent use of doses in excess of recommended levels is associated with increased risks of adverse reactions without evidence of additional benefits. Such treatment modality was evaluated in hospitalized psychiatric patients. During a 6-year recruitment period, a consecutive series of psychiatric inpatients receiving antipsychotic therapy were included. At admission, sociodemographic and clinical data, including antipsychotic drug use, were collected, and the 18-item version of the Brief Psychiatric Rating Scale was administered. At discharge, data on antipsychotic drug therapy were collected. Prescribed daily doses were converted into multiples of the defined daily doses. Using a cut-off score of a prescribed daily dose/defined daily dose as a ratio of more than 1.5 both at admission and at discharge assessments, a total of 62 (15.4%) patients persistently received high antipsychotic dose. With less stringent criteria (prescribed daily dose/defined daily dose as a ratio of more than 2), however, only 4.4% of the entire sample was persistently exposed to high antipsychotic doses. Bootstrapped linear regression analysis revealed that positive symptoms were positively associated with high antipsychotic dose, whereas negative symptoms were negatively associated with high antipsychotic dose. Antipsychotic polypharmacy at admission was the strongest predictor of persistently receiving antipsychotic doses in excess of recommended levels. This study showed that the use of high antipsychotic dosing is not an occasional event. Clinicians should consider that concurrent prescribing of two or more antipsychotic agents increases the probability of administering excessive dosing in the long-term.
Asunto(s)
Antipsicóticos/administración & dosificación , Trastornos Mentales/tratamiento farmacológico , Adulto , Antipsicóticos/uso terapéutico , Trastorno Bipolar/tratamiento farmacológico , Escalas de Valoración Psiquiátrica Breve , Trastorno Depresivo/tratamiento farmacológico , Prescripciones de Medicamentos , Quimioterapia Combinada , Utilización de Medicamentos/tendencias , Femenino , Hospitales Psiquiátricos , Humanos , Pacientes Internos , Italia , Masculino , Trastornos de la Personalidad/tratamiento farmacológico , Polifarmacia , Pautas de la Práctica en Medicina , Estudios Prospectivos , Esquizofrenia/tratamiento farmacológicoRESUMEN
OBJECTIVE: Community studies have failed to confirm that biochemically assessed thyroid status is significantly associated with psychopathology. However, it has been reported that self-reported thyroid disease is associated with symptoms of depression and anxiety. The objective of the current study was to determine whether self-reported thyroid disease is associated with elevated mental disorder prevalence in the general population. METHOD: Data from the Canadian Community Health Survey (CCHS) 1.2: Mental Health and Well-being were used. The CCHS 1.2 included the World Mental Health version of the Composite International Diagnostic Interview and collected self-report data about professionally diagnosed chronic medical conditions, including thyroid disease. RESULTS: Twelve-month and lifetime mental disorder prevalence was higher in subjects with thyroid disease than in subjects reporting no chronic conditions. For each condition examined (major depressive disorder, bipolar disorder, panic disorder/agoraphobia and social phobia), the 12-month and lifetime prevalence in subjects with thyroid disease resembled that of an aggregate category of subjects having other chronic conditions. After adjustment for age, sex and other chronic conditions, only social phobia was found to be associated with thyroid disease. CONCLUSIONS: People with thyroid disease are not a particularly high-need group for mental disorder screening or intervention, at least not in the community population.
Asunto(s)
Trastornos Mentales/epidemiología , Vigilancia de la Población/métodos , Encuestas y Cuestionarios , Enfermedades de la Tiroides/epidemiología , Adolescente , Adulto , Anciano , Manual Diagnóstico y Estadístico de los Trastornos Mentales , Humanos , Trastornos Mentales/diagnóstico , Trastorno de Pánico/epidemiología , Trastornos Fóbicos/epidemiología , Prevalencia , Trastornos Relacionados con Sustancias/epidemiología , Enfermedades de la Tiroides/diagnóstico , Enfermedades de la Tiroides/psicología , Tirotropina/sangreRESUMEN
AIM: The objective of this study was to identify clinical and demographic factors that may be associated with benzodiazepine treatment, to describe the reported reasons for use of these medications and to appraise the pattern of use in relation to standard guidelines in a general population sample. METHODS: Telephone survey methods were employed to select a sample of 3345 people between the ages of 18 and 64. A computer assisted telephone interview, including the Mini Neuropsychiatric Diagnostic Interview (MINI), was administered. Estimates were weighted for design features and population demographics. RESULTS: The overall prevalence of benzodiazepines use was 3.3% (95% confidence interval [CI] 2.6 to 4.1%). There was a higher frequency of medication use in women than men, among respondents who were widowed, separated or divorced, and those with lower levels of education. In relation to MINI diagnosis, diagnoses of Panic Disorder and Major Depression increased the probability of taking benzodiazepines. The reported main reason for use was "Sleep disorders" (68.9%), "Anxiety" (35.8%), "Depression" (27.8%) and "Pain management" (21.2%). More than 80% of subjects were taking benzodiazepines for more than one year. CONCLUSIONS: When compared to previous estimates, the lower frequency of benzodiazepines use suggests that there has been improvement in their evidence-based use at a population level. However our results once more confirm the difficulty stopping the use of these medications once they have been started. Further randomized control studies may help clinicians in having a better practical approach to rational benzodiazepine use.
Asunto(s)
Benzodiazepinas/uso terapéutico , Adolescente , Adulto , Anciano , Alberta , Utilización de Medicamentos/estadística & datos numéricos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto JovenRESUMEN
BACKGROUND: One third to two thirds of people with schizophrenia have persistent psychotic symptoms despite clozapine treatment. Under real-world circumstances, the need to provide effective therapeutic interventions to patients who do not have an optimal response to clozapine has been cited as the most common reason for simultaneously prescribing a second antipsychotic drug in combination treatment strategies. In a clinical area where the pressing need of providing therapeutic answers has progressively increased the occurrence of antipsychotic polypharmacy, despite the lack of robust evidence of its efficacy, we sought to implement a pre-planned protocol where two alternative therapeutic answers are systematically provided and evaluated within the context of a pragmatic, multicentre, independent randomised study. METHODS/DESIGN: The principal clinical question to be answered by the present project is the relative efficacy and tolerability of combination treatment with clozapine plus aripiprazole compared with combination treatment with clozapine plus haloperidol in patients with an incomplete response to treatment with clozapine over an appropriate period of time. This project is a prospective, multicentre, randomized, parallel-group, superiority trial that follow patients over a period of 12 months. Withdrawal from allocated treatment within 3 months is the primary outcome. DISCUSSION: The implementation of the protocol presented here shows that it is possible to create a network of community psychiatric services that accept the idea of using their everyday clinical practice to produce randomised knowledge. The employed pragmatic attitude allowed to randomly allocate more than 100 individuals, which means that this study is the largest antipsychotic combination trial conducted so far in Western countries. We expect that the current project, by generating evidence on whether it is clinically useful to combine clozapine with aripiprazole rather than with haloperidol, provides physicians with a solid evidence base to be directly applied in the routine care of patients with schizophrenia.
Asunto(s)
Antipsicóticos/uso terapéutico , Clozapina/uso terapéutico , Resistencia a Medicamentos , Haloperidol/uso terapéutico , Piperazinas/uso terapéutico , Quinolonas/uso terapéutico , Esquizofrenia/tratamiento farmacológico , Psicología del Esquizofrénico , Aripiprazol , Protocolos Clínicos , Quimioterapia Combinada , Regulación Gubernamental , Humanos , Italia , Estudios Prospectivos , Proyectos de Investigación/legislación & jurisprudencia , Resultado del TratamientoRESUMEN
PURPOSE: To describe reasons reported by physicians making recommendations for treatment with antidepressant medications. METHODS: Data collected by IMS Health Canada in a database called the Canadian Disease and Therapeutic Index (CDTI) were used in this analysis. CDTI data are collected from a representative sample of office-based physicians who complete diaries in their practices during selected sampling periods. A drug recommendation is recorded each time a treatment is recommended. The data are weighted to produce national estimates of the frequency of such recommendations. RESULTS: The frequency of recommendations for antidepressant treatment increased between 2000 and 2004. However, there was a slight decrease in 2005. Two types of antidepressant medications, tricyclic antidepressants (TCAs) and trazodone showed distinct patterns of use. TCAs were more commonly used for non-psychiatric indications than for psychiatric indications, especially for sleep- and pain-related reasons. Trazodone was frequently recommended for sleep problems. The proportion of recommendations for depressive disorders for antidepressants as a group remained stable over the 5-year study period. CONCLUSIONS: About one-third of antidepressant recommendations are for reasons other than depression. It can no longer be assumed that the frequency of antidepressant use is a measure of the frequency of pharmacological depression treatment. However, prescription data may be useful for tracking trends.
Asunto(s)
Antidepresivos/uso terapéutico , Pautas de la Práctica en Medicina/estadística & datos numéricos , Antidepresivos Tricíclicos/uso terapéutico , Canadá , Bases de Datos Factuales , Depresión/tratamiento farmacológico , Humanos , Dolor/tratamiento farmacológico , Farmacoepidemiología/métodos , Médicos , Trastornos del Sueño-Vigilia/tratamiento farmacológico , Trazodona/uso terapéuticoRESUMEN
AIMS: The term "presenteeism" is used to describe workers who are present in the workforce, but who are not functioning at full capacity. The objective of the study was to describe the impact of mood and anxiety disorders on presenteeism in a population sample. METHODS: Random digit dialing was used to select a sample of n=3345 subjects between the ages of 18 and 64. A computer assisted telephone interview that included the Mini Neuropsychiatric Diagnostic Interview (MINI), the Stanford Presenteeism Scale 6 (SPS-6) and a pharmacoepidemiology module was administered. RESULTS: Among subjects with comorbid mood and anxiety disorders 75.0% reported interference with their work compared with only 13.3% of subjects without mood or anxiety disorders. Mood and anxiety disorders were associated with lower presenteeism ratings. Regression analysis uncovered a significant gender by anxiety disorder interaction, indicating that the effect of anxiety disorders was greater in men than women. CONCLUSIONS: This is the first study to report the impact of mental disorders on presenteeism in a general population sample. The results confirm that the problem of presenteeism is not restricted to specific occupational groups, but is instead a widespread problem in the general population.
Asunto(s)
Trastornos de Ansiedad/epidemiología , Empleo/estadística & datos numéricos , Trastornos del Humor/epidemiología , Adolescente , Adulto , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Vigilancia de la Población/métodos , Población Rural/estadística & datos numéricos , Encuestas y CuestionariosRESUMEN
OBJECTIVE: Population-based data about depression treatment are largely restricted to estimates of the frequency of antidepressant (AD) use. Such frequencies are difficult to interpret in the absence of information about dosages, reasons for taking the medications, and participation in nonpharmacologic treatment. The objective of this study was to describe the pattern of treatment for major depression (MD) in Alberta. METHOD: Telephone survey methods were employed. Random digit dialing was used to select a sample of 3345 household residents aged 18 to 64 years in Alberta. A computer-assisted telephone interview that included the Mini Neuropsychiatric Diagnostic Interview and questions about pharmacotherapy and psychotherapy was administered. Estimates were weighted for design features and population demographics. RESULTS: The point prevalence of MD was 4.4% (95% confidence interval [CI], 3.4% to 5.5%), and the overall prevalence of current AD use was 7.4% (95% CI, 6.2% to 8.6%). The ADs taken most commonly, serotonin-specific reuptake inhibitors, were taken at therapeutic dosages 87.4% of the time. Most (80.7%) of those taking ADs reported taking them for more than 1 year. The frequency of receiving counselling, psychotherapy, or talk therapy was 3.9% overall and 14.3% in respondents with MD. However, most of these subjects were unable to name the type of counselling they were receiving. CONCLUSIONS: When compared with previous estimates, these results suggest continued progress in the delivery of evidence-based care to the population. There is room for additional improvement, especially in the provision of nonpharmacologic treatment.